News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Drug Development
U.S. FDA Staff Questions Small ChemGenics Pharmaceuticals Study
February 8, 2010
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Reuters -- A small study of ChemGenex Pharmaceuticals Ltd's experimental drug for leukemia patients with a certain genetic mutation showed a low response rate, U.S. health regulatory staff said in documents released on Monday.
Twitter
LinkedIn
Facebook
Email
Print
Clinical research
Phase II
Food and Drug Administration (FDA)
MORE ON THIS TOPIC
Allergies
Regeneron’s Antibodies Block Cat and Birch Allergies With ‘Robust Activity’
September 9, 2025
·
2 min read
·
Tristan Manalac
Drug Development
If Data Is the New Oil, AI Is the Refinery
September 8, 2025
·
5 min read
·
Lori Ellis
Neuroscience
Alkermes One Ups Takeda in Narcolepsy, Clearing Cognitive Impairments in Mid-Stage Trial
September 8, 2025
·
2 min read
·
Dan Samorodnitsky
Neuroscience
Rapport Jumps 180% on ‘Best Case’ Mid-Stage Data for Epilepsy Pill
September 8, 2025
·
2 min read
·
Heather McKenzie